On June 1, 2021 BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, reported that two abstracts have been accepted for online publication for the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting (Press release, BostonGene, JUN 1, 2021, View Source [SID1234583344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have multiple abstracts accepted for online publication," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our findings underscore the importance of the application of novel and cutting-edge analytical tools to understand the composition and activity of the tumor and the microenvironment, which will improve treatment outcomes for cancer patients."

The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO (Free ASCO Whitepaper) Annual Meeting Proceedings.

Details about the abstracts selected for publication can be found below:

Abstract Number: e15050
Title: The development of a computational machine learning tool to decipher malignant cell gene expression from complex tumor tissue

Complex tumor tissue is composed of malignant cells and diverse tumor microenvironment (TME) cellular populations. The percentage of malignant cells present in tumor tissue varies by cancer type, with percentages sometimes falling below 10%. TME cellular transcripts may comprise the majority of the total transcripts in a tumor, potentially resulting in biases during biomarker development and for clinical decision-making. A computational tool was created to "subtract" TME-specific gene expression from total gene expression in an array of solid tumors, producing in silico "purified” malignant cell gene expression.

Abstract Number: e15085
Title: Analytical and clinical validation of the BostonGene Tumor Portrait assay

Analysis of the genetic and transcriptomic profile of solid tumors using next-generation sequencing (NGS) assays is fundamental to propel precision medicine into clinical practice. NGS technology applied to tumor analysis allows for the characterization of somatic alterations, clonality, altered gene expression, and other parameters using a small amount of tissue. The BostonGene Tumor Portrait TestsTM, which integrate whole-exome sequencing (WES) and mRNA sequencing (RNA-seq), were developed to uncover cancer-promoting and -suppressing activity of the tumor and the tumor microenvironment (TME).

On June 1, 2021 Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, reported that data will be presented from multiple studies across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Annual Meeting, June 4-8 and the European Hematology Association (EHA) (Free EHA Whitepaper) 2021 Virtual Congress, June 9-17 (Press release, Servier, JUN 1, 2021, View Source [SID1234583359]). Data presented at ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) include multiple company-sponsored and investigator-initiated trials, which underscore the depth and breadth of Servier’s oncology portfolio that is making strides toward addressing unmet needs of those living with cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Three abstracts have been selected for oral presentation, spanning multiple hard-to-treat solid tumor types, including glioma, biliary tract cancer, and colorectal cancer. These presentations highlight the potential role of IDH inhibition and the company’s overall innovative research portfolio in generating superior outcomes over current standards of care based on precision approaches. Research from several investigator-initiated trials will also be shared. These studies investigate evolving the standard of care in advanced cancers through the use of combination approaches in metastatic colorectal cancer, myeloid malignancies, gastric and gastroesophageal adenocarcinoma, and biliary tract cancer.

In addition, there will be an encore poster presentation of the final results from ClarlDHy, the first and only randomized Phase 3 trial for previously treated IDH1-mutated cholangiocarcinoma. Data from this study were included in the company’s supplemental New Drug Application for TIBSOVO, which was recently accepted and granted Priority Review by the U.S. Food and Drug Administration. Currently, there are no approved systemic therapies for IDH1-mutated cholangiocarcinoma and limited chemotherapy options are available for patients with advanced disease.

"Our presence at this year’s ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) showcase the very focused approach we are taking to place an emphasis on difficult-to-treat cancers with significant unmet need," said David K. Lee, CEO, Servier Pharmaceuticals. "We believe that our leadership in hematology and growing position in solid tumors ensures we are well poised to deliver more life-changing medicines to a greater number of individuals impacted by cancer worldwide."

Servier has experienced tremendous growth in the past several years. Much of this expansion is in the oncology space where the company is now allocating 50 percent of its research and development investment. With 19 oncology assets at varying stages of clinical development, and 20 research projects1, Servier is addressing areas of significant unmet need and difficult-to-treat cancers that target different types of lymphoma and leukemia, as well as solid tumors including gastrointestinal and lung cancers.

"Our significant presence at these key congresses is reflective of the successful expansion of our research and development for a variety of tumor types to benefit patients," said Claude Bertrand, Executive Vice President of Research and Development, Servier Group. "We are excited to present data across our hematology and solid tumor portfolio including research on the potential of IDH inhibition in the treatment of cancers with high unmet needs."

Key highlights of data at ASCO (Free ASCO Whitepaper), sponsored by Servier, are listed below and are available online on the ASCO (Free ASCO Whitepaper) website: View Source

Abstract #2008: Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG)

Date & Time: Monday, June 7, 2021 at 8:00 a.m. EDT
Oral Session: Oral Abstract Session, Central Nervous System Tumors
Presenting Author: I. Mellinghoff
Abstract #4069: Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation

Date & Time: Friday, June 4, 2021 at 9:00 a.m. EDT
Poster Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Presenting Author: G.K. Abou-Alfa
Abstract #3526: Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: interim results of the TALLISUR study

Date & Time: Friday, June 4, 2021 at 9:00 a.m. EDT
Poster Session: Gastrointestinal Cancer – Colorectal and Anal
Presenting Author: M. Karthaus
Investigator-initiated trials to be presented at ASCO (Free ASCO Whitepaper) include:

Abstract #4006: Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY)

Date & Time: Saturday, June 5, 2021 at 1:45 p.m. EDT
Short Oral Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Presenting Author: C. Yoo
Abstract #7012: A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Date & Time: Friday, June 4, 2021 at 9:00 a.m. EDT
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Presenting Author: C.D. DiNardo
Servier will be hosting five continuing medical educational programs at ASCO (Free ASCO Whitepaper) focusing on hematology and solid tumors including:

Hematology

"The AML ‘Hot Seat’: Challenging the Experts on How They Treat and Individualize Care with Novel Therapies," sponsored with Physicians’ Education Resource, June 4, 2021
"Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics," sponsored with PeerView Oncology, June 4, 2021
"Exploring a Continually Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes," sponsored with National Comprehensive Cancer Network, June 4, 2021
Solid Tumors

"How Evolving Genomics and Molecular Testing are Moving the Treatment of Cholangiocarcinoma Forward," sponsored with Physicians’ Education Resource, June 6, 2021
"Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly-Available and Innovative Therapeutics to Deliver Precision-Based Care," sponsored with PeerView Oncology, June 4, 2021
In addition, an encore presentation from ASCO (Free ASCO Whitepaper) for an investigator-initiated trial will be presented at EHA (Free EHA Whitepaper):

Abstract #S136: A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1 mutated myeloid malignancies

Date & Time: Friday, June 11, 2021 at 9:00 CEST (3:00 a.m. EDT)
Oral Session: Developments in AML therapy
Presenting Author: C. Lachowiez

On June 1, 2021 Cardiff Oncology, Inc. (the "Company") Presented its corporate slide presentation (Presentation, Cardiff Oncology, JUN 1, 2021, View Source [SID1234583312]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 1, 2021 Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, reported that invites investors and the general public to listen to webcasts at the following investor conferences (Press release, Myovant Sciences, JUN 1, 2021, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-present-upcoming-investor-conferences-3 [SID1234583328]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 42nd Annual Global Healthcare Virtual Conference on June 8, 2021 at 4:40 p.m. Eastern Time. Company management will participate in a fireside chat.

JMP Securities Life Sciences Conference on June 17, 2021 at 10:00 a.m. Eastern Time. Company management will participate in a fireside chat.
The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

On June 1, 2021 Tempus, a leader in artificial intelligence and precision medicine, reported eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place virtually from June 4 – 8 (Press release, Tempus, JUN 1, 2021, View Source [SID1234583345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These high impact ASCO (Free ASCO Whitepaper) presentations from Tempus collaborators and investigators illustrate the power of over 35 petabytes worth of clinical and molecular data collected since Tempus started five years ago," said Dr. Kimberly Blackwell, Chief Medical Officer at Tempus. "By combining extensive tumor and germline genomic profiling with just-in-time clinical trial matching in our TIME Trial Network, Tempus is bringing the right treatments to patients facing cancer in a data-driven and expedited way. I am really excited to share how our multi-modal data is helping transform precision cancer care."

One abstract selected for oral presentation and four abstracts selected for poster presentation at ASCO (Free ASCO Whitepaper) 2021 are highlighted below. The complete list of Tempus-affiliated abstracts and poster presentations can be found at www.tempus.com/publications.

Multimodal Profiling of Biliary Tract Cancers Detects Potentially Actionable Biomarkers and Differences in Immune Signatures Between Subtypes
Overview: This study examined the relationship between the mutational landscape and immune-related RNA signatures of different biliary tract cancer subtypes, including intrahepatic, extrahepatic cholangiocarcinoma and gallbladder cancers. Based on RNA signatures, gallbladder cancers had higher expression of select immune signatures compared to intrahepatic cancers.
This abstract has been accepted for oral presentation in the "Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary" session on June 5 from 1:45 – 4:45 pm CDT.
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology (IO) Biomarkers
Overview: Using Lens, Tempus’ cloud-based data and analytics platform for drug discovery and development, the de-identified records of 79,004 patients diagnosed with various cancer types who underwent Tempus xT and xF next generation sequencing were analyzed to study the association between KRAS variants and cancer subtypes. Tumors harboring KRASG12C were associated with smoking status and had significantly higher tumor mutational burden and programmed death-ligand 1 expression, which are important markers for immunotherapy.
This abstract has been accepted for poster presentation in the "Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology" track and will be available on June 4 at 7:00 am CDT.
The TIME Trial Network to Facilitate Rapid Clinical Trial Activation, Patient Screening, and Enrollment in Molecularly Targeted Trials
Overview: Tempus’ TIME Trial Network was established to increase access and participation in clinical trials by applying a rapid just-in-time activation model. In the last quarter of 2020, six unique interventional clinical trials were activated across eight US states in the TIME Trial Network. Over a 3-month period, on average, TIME Trial sites were activated in 9.4 days (compared to the 20+ week industry-wide average), and patient consent was completed in 4.5 days.
This abstract has been accepted for poster presentation in the "Care Delivery and Regulatory Policy" track and will be available on June 4 at 7:00 am CDT.
Rate of Incidental Germline Findings Detected by Tumor-Normal Matched Sequencing in Cancer Types Lacking Hereditary Cancer Testing Guidelines
Overview: This study analyzed 21,395 de-identified records from patients across select cancer types sequenced using Tempus xT Tumor-normal matched approach. Incidental P/LP germline variants were detected in 6.4% of patients diagnosed with the 6 select cancer types that lack hereditary cancer testing guidelines, with the highest prevalence in patients with bladder (7.9%), brain (6.5%), and lung (6.5%) cancers. The identification of such germline findings may have clinical implications for the patients, as well as at-risk family members, resulting in the opportunity for genetic counseling and risk-stratified intervention.
This abstract has been accepted for poster presentation in the "Prevention, Risk Reduction, and Hereditary Cancer" track and will be available on June 4 at 7:00 am CDT.
Comprehensive Genomic Profiling in Advanced/Metastatic Colorectal Cancer: Number Needed to Test and Budget Impact of Expanded First-Line Use
Overview: A decision analytical model, based on Tempus xT, was developed to determine the impact of first-line genomic profiling in detection of actionable alterations in metastatic colorectal cancer, along with the associated diagnostic testing costs in a modeled US health plan setting of 5 million lives. Replacing 20% of standard of care testing with Tempus xT was associated with a small incremental testing cost, but led to identification of actionable alterations in a meaningful number of patients.
This abstract has been accepted for publication in the "Health Services Research and Quality Improvement" session and will be available on June 4 at 7:00 am CDT.